CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
The immunogenicity and safety of AdCLD-CoV19-1 OMI (5.0x10\^10 VP (0.5 mL)/dose/Vial) administered as a booster in healthy adults aged 19 years old a...
Phase 3
Seoul, Korea, Republic of and 16 other locations
legal age for adult in each country) with confirmed mild or moderate COVID-19 tested positive with a real time reverse transcriptio...
Phase 2, Phase 3
Seoul, Korea, Republic of and 2 other locations
Parallel-treatment Group, Adaptive Design, Multi-center, Phase 2b/3 Trial to Evaluate Efficacy and Safety of NuSepin® Intravenous Infusion in COVID...
Phase 2, Phase 3
Incheon, Namdong-gu, Korea, Republic of
known SARS-CoV-2 variants of concern for pre-exposure prophylaxis of COVID-19.The aim of the Phase I/III study (Parent Study) will -...
Phase 2, Phase 3
Seoul, Korea, Republic of and 214 other locations
seek to enroll immunocompromised patients with Lower Tract parainfluenza infection.It also contains a sub-study to enroll patients with severe COVID...
Phase 3
Seoul, Gyeonggi-do, Korea, Republic of and 59 other locations
This clinical trial will evaluate the safety, tolerability and immunogenicity of GLS-5310 DNA vaccine against SARS-CoV-2(COVID-19) ...
Phase 1, Phase 2
Seoul, Korea, Republic of
This clinical trial will evaluate the safety, tolerability and efficacy of GLS-1027 in the prevention of severe pneumonitis caused by SARS-CoV-2 infe...
Phase 2
Seoul, Korea, Republic of and 16 other locations
This study is to evaluate the safety, reactogenicity, and immunogenicity of the QTP104 vaccine against SARS-CoV-2 infection in healthy adults.
Phase 1
Seoul, Korea, Republic of and 1 other location
A dose-escalation, double-blinded, randomized, placebo-controlled phase 1 study to assess the safety, reactogenicity, and immunogenicity of a SARS-Co...
Phase 1
Seoul, Korea, Republic of
This study will be conducted to evaluate the efficacy of lecanemab in participants with early Alzheimer's disease (EAD) by determining the superiorit...
Phase 3
Seoul, Korea, Republic of and 246 other locations
Clinical trials
Research sites
Resources
Legal